Introgen Therapeutics Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Introgen Therapeutics

INGN 6.800

+1.9%

Dec 26 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (533)	5/8/2006 4:25:52 PM
From: Jibacoa	Read Replies (1) of 802

Introgen's ADVEXIN p53 Therapy Provided to Cancer Patients With Li-Fraumeni Syndrome Monday May 8, 3:39 pm ET ADVEXIN Available on Compassionate Use Basis to Qualified Patients AUSTIN, Texas, May 8 /PRNewswire-FirstCall/ -- Introgen Therapeutics' ADVEXIN p53 therapy has been successfully used to treat a Li-Fraumeni Syndrome cancer patient on a compassionate use basis under a protocol authorized by the fda Based upon the encouraging clinical findings, ADVEXIN p53 therapy will be available on a compassionate basis to qualified Li-Fraumeni Syndrome patients with tumors refractory to standard treatment through protocols at qualifying institutions. About Li-Fraumeni Syndrome LFS is an inherited genetic disorder that greatly increases the risk of developing several types of cancer typically with initial occurrence at a young age. The majority of LFS families have inherited mutations in the p53 tumor suppressor gene. The treatment of LFS tumors with ADVEXIN represents therapy targeted to the molecular defect underlying the cause and progression of these cancers. Snip biz.yahoo.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next